Amneal Pharmaceuticals (AMRX) Tops Q2 EPS by 8c, raises guidance

Amneal Pharmaceuticals (NASDAQ: AMRX) reported Q2 EPS of $0.25, $0.08 better than the analyst estimate of $0.17. Revenue for the quarter came in at $725 million versus the consensus estimate of $748.18 million.

GUIDANCE:

Amneal Pharmaceuticals sees FY2025 EPS of $0.70-$0.75, versus the consensus of $0.71. Amneal Pharmaceuticals sees FY2025 revenue of $3-3.1 billion, versus the consensus of $3.017 billion.

For earnings history and earnings-related data on Amneal Pharmaceuticals (AMRX) click here.

You May Also Be Interested In

• ArcelorMittal (MT:NA) (MT) PT Raised to EUR65 at Jefferies
• CME Group (CME) call put ratio 2 calls to 1 put with a focus on September 230 calls
• Nvidia Says "Our Roadmap Is Intact" In Response To Delay Report - Bloomberg